Why the study?
Does digoxin as baseline initial therapy increase mortality or hospitalization in patients with paroxysmal and persistent atrial fibrillation?
Does digoxin as baseline initial therapy increase mortality or hospitalization in patients with paroxysmal and persistent atrial fibrillation?
In a post hoc analysis of the AFFIRM trial, baseline digoxin therapy was not associated with increased mortality or hospitalization in patients with atrial fibrillation.
No excess risk with digoxin in AF; hypothesis-generating and should not yet change practice.
In patients with paroxysmal and persistent AF, we found no evidence of increased mortality or hospitalization in those taking digoxin as baseline initial therapy.
No takes yet. Share an insight, caveat, or question.
Gheorghiade et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: